Roche announces the failure of a trial for its treatment against Alzheimer’s disease

“Crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation that causes early-onset Alzheimer’s disease,” the drugmaker said in a statement.

The Colombian Alzheimer’s Prevention Initiative (API) trial in autosomal dominant Alzheimer’s disease (ADAD) evaluated the ability of crenezumab to slow or prevent disease in people without cognitive impairment who are carriers of a specific genetic mutation, resulting in an early onset of the disease, Roche said.

Last month, the Basel company had already suffered a major setback by announcing the failure of a phase III trial on the use of tiragolumab associated with Tecentriq to treat a form of lung cancer.

(Reportage by Silke Koltrowitz; edited by Kate Entringer)

See also  Do you want to study a medical specialty in Cuba? CONACYT opens its call for applications 2021-2022, REQUIREMENTS



Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Social Media

Most Popular

On Key

Related Posts